Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -43.95% is 29% below its 5-year average of -34.05%, around the middle of its 5-year range (-56.69%–-17.41%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.37% below its 12-month average of -42.11%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -43.95%.
RETURN ON EQUITY (ROE)
-43.95%
RETURN ON EQUITY (ROE) AVG TTM
-42.11%
RETURN ON EQUITY (ROE) AVG 3Y
-31.76%
RETURN ON EQUITY (ROE) AVG 5Y
-34.05%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-4.37%
CURRENT VS 3Y AVG
-38.41%
CURRENT VS 5Y AVG
-29.09%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-36.00%
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
-22.07%
vs the sector median at left
4D Molecular Therapeutics, Inc.
Market Cap
$675.41M
Return on Equity (ROE)
-43.95%
TTM Avg
-42.11%
3Y Avg
-31.76%
5Y Avg
-34.05%
Market Cap
$688.14M
Return on Equity (ROE)
-108.93%
TTM Avg
-72.41%
3Y Avg
-64.95%
5Y Avg
-55.74%
Market Cap
$698.60M
Return on Equity (ROE)
-113.05%
TTM Avg
-95.98%
3Y Avg
-72.88%
5Y Avg
-73.85%
Market Cap
$643.37M
Return on Equity (ROE)
-41.56%
TTM Avg
-67.38%
3Y Avg
-49.66%
5Y Avg
-56.07%
Market Cap
$707.86M
Return on Equity (ROE)
-75.79%
TTM Avg
-55.51%
3Y Avg
-59.06%
5Y Avg
-60.41%
Market Cap
$642.31M
Return on Equity (ROE)
-21.51%
TTM Avg
-20.05%
3Y Avg
-35.91%
5Y Avg
-26.18%
Market Cap
$709.33M
Return on Equity (ROE)
15.36%
TTM Avg
25.54%
3Y Avg
15.72%
5Y Avg
18.75%
Market Cap
$637.59M
Return on Equity (ROE)
-8.42%
TTM Avg
-4.61%
3Y Avg
-3.17%
5Y Avg
11.46%
Market Cap
$632.76M
Return on Equity (ROE)
-24.06%
TTM Avg
-36.09%
3Y Avg
-34.99%
5Y Avg
-44.03%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $675.41M | -43.95% | -42.11% | -31.76% | -34.05% |
| Annexon, Inc. (ANNX)vs › | $688.14M | -108.93% | -72.41% | -64.95% | -55.74% |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | -113.05% | -95.98% | -72.88% | -73.85% |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | -41.56% | -67.38% | -49.66% | -56.07% |
| Helus Pharma Inc. (HELP)vs › | $707.86M | -75.79% | -55.51% | -59.06% | -60.41% |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | -21.51% | -20.05% | -35.91% | -26.18% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 15.36% | 25.54% | 15.72% | 18.75% |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | -8.42% | -4.61% | -3.17% | 11.46% |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | -24.06% | -36.09% | -34.99% | -44.03% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | N/A | -222.26% | 276.12% | 157.82% |
ROE
-44.0%
ROA
-36.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -43.95% |
| 2026-03-31 | -35.61% |
| 2025-12-31 | -27.71% |
| 2025-09-30 | -56.69% |
| 2025-06-30 | -46.60% |
| 2025-03-31 | -37.56% |
| 2024-12-31 | -31.51% |
| 2024-09-30 | -25.95% |
| 2024-06-30 | -18.68% |
| 2024-03-31 | -17.41% |
| 2023-12-31 | -32.76% |
| 2023-09-30 | -29.08% |
| 2023-06-30 | -34.25% |
| 2023-03-31 | -50.24% |
| 2022-12-31 | -46.47% |
| 2022-09-30 | -41.84% |
| 2022-06-30 | -37.34% |
| 2022-03-31 | -27.44% |
| 2021-12-31 | -22.35% |
| 2021-09-30 | -29.80% |
| 2021-06-30 | -21.76% |
| 2021-03-31 | -24.72% |
| 2020-12-31 | -22.11% |
| 2020-09-30 | -74.49% |
| 2020-03-31 | -180.63% |
| 2019-09-30 | -58.30% |
| 2019-03-31 | -25.08% |
